Ad5-nCoV
Sign in to saveAlso known as CanSino Biologics COVID-19 vaccine candidate, Convidecia, CanSino vaccine, PakVak
In the Vinony graph
Vinony's link graph records 1,527 inbound references to Ad5-nCoV, and connects out to Gam-COVID-Vac, SARS-CoV-2 and COVID-19 pandemic in Italy.
It is catalogued under topics including Adenoviridae, Chemical pages without ChemSpiderID and Chinese COVID-19 vaccines.
Vinony links it to 20 Wikipedia language editions.
Key facts
- Drug.drug_name
- AD5-nCOV
- Drug.type
- vaccine
- Drug.image
- CanSino Convidecia.jpg
- Drug.caption
- A multi-dose vial of Convidecia (AD5-nCOV) filled and finished in Mexico
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- viral
- Drug.tradename
- Convidecia
- Drug.legal_status
- Full list of Convidecia authorizations
- Drug.routes_of_administration
- Intramuscular, Nebulizer
- Drug.CAS_number
- 2540656-88-8
- Drug.ATC_prefix
- J07
- Drug.ATC_suffix
- BN02
- Drug.DrugBank
- DB15655
- Drug.UNII
- 5AHC3V2UQS
- Drug.synonyms
- PakVac
via Wikipedia infobox
Wikidata facts
- Instance of
- vaccine
- Official name
- PakVak
- Image
- CanSino Convidecia.jpg
Show 5 more facts
- on focus list of Wikimedia project
- WikiProject COVID-19
- vaccine for
- COVID-19
- side effect
- fatigue
- route of administration
- intramuscular injection
- Commons category
- Convidecia
via Wikidata · CC0
~11 min read
Encyclopedic overview
16 sectionsContents
- Efficacy
- Pharmacology
- Manufacturing
- History
- Clinical trials
- Phase I-II
- Trials of inhaled version (Convidecia Air)
- Phase III
- Combination trials
- Authorizations
- Economics
- Americas
- Asia
- References
- Further reading
- External links
AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.
In February 2021, global data from Phase III trials and 101 COVID cases showed that the intramuscular version of the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease. It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial. Convidecia is similar to other viral vector vaccines like AZD1222, Gam-COVID-Vac, and Ad26.COV2.S. Its single-dose regimen and normal refrigerator storage requirement (2° to 8 °C) could make it a favorable vaccine option for many countries. In May 2022, the World Health Organization issued an emergency use listing for the vaccine.
Excerpted from Wikipedia’s “Ad5-nCoV” article, available under the CC BY-SA 4.0 licence.